Developer docs
API playgroundTry for free, no card

Search company profiles

Sanfer

Full company profile

uuid00024il

Namestring
Sanfer
Legal namestring
Laboratorios Sanfer, S.A. de C.V.
Websiteurl
sanfer.com.mx
Company typeenum
Private
Founded yearint
1941
Descriptiontext

Laboratorios Sanfer, S.A. de C.V. is a privately held Mexican multinational pharmaceutical company founded in 1941, headquartered in Mexico City, with operations in more than 25 countries across Latin America, the Caribbean, North America, Europe, Africa, the Middle East, and Asia. The company manufactures, markets, and distributes prescription medications, over-the-counter (OTC) consumer health products, animal health products (vaccines, antibiotics, antiparasitics, diagnostics), and poultry genetics through 20 manufacturing sites and a workforce of more than 12,000 employees. Sanfer's therapeutic footprint spans sterile injectables (ampoules, vials, lyophilized, prefilled syringes), oral solids and suspensions, semisolids, soft gelatin capsules, oncological steriles, antibiotics, and biologics, with capabilities reinforced by acquisitions including Probiomed (biotech, 2021) and Vitalis (Colombian sterile injectables leader, 2024).

Sanfer operates through a portfolio of legacy and acquired brands — including Mavi Farmacéutica, More Pharma, Pharmadorf (Argentina), Laboratorios Bussie and Labinco (Colombia), Laboratorios Pasteur (Chile), and Laboratorios Portugal (Peru) — alongside sub-brands such as Sanfer Salud Animal, Sanfer ALPES/IMSA (poultry genetics), and Sanfer Conecta (a digital platform providing healthcare professionals with access to more than 300,000 medical books, articles, webinars, and 3D anatomical models). The company sells through a multi-channel distribution network: retail pharmacy chains, mass retailers, e-commerce platforms (Amazon, Cornershop, Rappi, Farmalisto), and the Sanfer Conecta app for healthcare professionals.

Sanfer's commercial model is a sales-led, multi-channel distribution operation across prescription, OTC, animal health, and biologics, with revenue derived from unit sales of branded pharmaceutical products to consumers via pharmacies and retailers, to veterinarians and animal health providers, and to healthcare institutions across Latin America. Quality and regulatory certifications from COFEPRIS, INVIMA, DIGEMID, EMA, ISO, and FAMI-QS underpin the international expansion. The company has pursued an aggressive inorganic growth strategy, backed by institutional capital from La Caisse and General Atlantic (a $500M round in 2019), with recent strategic moves including the Vitalis acquisition (2024) and an exclusive distribution partnership with Hanmi Pharmaceutical for GLP-1 and diabetes therapies in Mexico (2026).

Short descriptiontext

Sanfer is a privately held Mexican multinational pharmaceutical company founded in 1941 that manufactures and distributes prescription, OTC, animal health, and biologic products through 20 manufacturing sites across 25+ countries, serving consumers, healthcare professionals, and veterinarians in Latin America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMexico City, Mexico
HQ citystring
Mexico City
HQ countrystring
Mexico
HQ regionstring
Latin America
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, over-the-counter medications, animal health products, sterile injectables manufacturing, pharmaceutical distribution
Industry2 codes
PRIMARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
SECONDARYHLAMAKAI
Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Animal Food Manufacturing3111
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Medications
TypeSubscription Recurring
Description

Prescription pharmaceutical products sold through pharmacies and healthcare providers in Mexico and Latin America

sanfer.com.mx
2Over-the-Counter (OTC) Products
TypeOne Time License
Description

OTC pharmaceutical and consumer health products sold directly to consumers through pharmacies and retail chains

sanfer.com.mx
3Animal Health Products
TypeOne Time License
Description

Veterinary pharmaceuticals, vaccines, and health products for animals sold to veterinarians and animal health providers

sanfer.com.mx
4Poultry Genetics
TypeOne Time License
Description

Poultry genetics products through Sanfer ALPES and IMSA for the pharmaceutical and agricultural markets

sanfer.com.mx
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Sanfer ALPES
Description

Poultry genetics company

sanfer.com.mx
+4 more records
Core offering1 text field

Laboratorios Sanfer manufactures, markets, and sells branded prescription and over-the-counter pharmaceutical products across multiple therapeutic areas through 20 manufacturing sites in Mexico and Latin America. The company also produces animal health pharmaceuticals, vaccines, and diagnostics through its Sanfer Salud Animal division, and operates integrated poultry genetics businesses (Sanfer ALPES and Sanfer IMSA). It supplements its product portfolio with the Sanfer Conecta digital platform that gives healthcare professionals access to product information, a medical library, and clinical resources.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Laboratorios Sanfer is a leading Mexican pharmaceutical company with operations in 25+ countries across Latin America, operating as a diversified pharmaceutical group. The company offers a comprehensive portfolio of prescription medications, OTC (over-the-counter) products, nutraceuticals/supplements, and animal health products through multiple divisions and acquired brands. The core product ecosystem includes Sanfer Conecta, a digital platform for healthcare professionals providing access to product catalogs, medical libraries, webinars, and 3D anatomical models. The OTC portfolio includes analgesic/antipyretic products (AC-Fast, Algitrin, Tabalón, Lonol), antihistamines (Andantol), gastrointestinal products (Treda, Optazol-KO), antifungal products (Desenex, Ting), and wound care products (Microdacyn). The nutraceutical line includes Biometrix variants (Performance, AOX, Q-10), Meta-R metabiotics, and Eternal Vitamin E supplements. Animal health offerings are provided through Sanfer Salud Animal with vaccines, antibiotics, and diagnostic products. Sanfer has expanded through strategic acquisitions including Vitalis (sterile injectables), Probiomed (biotech), Mavi Farmacéutica, More Pharma, Laboratorios Portugal, Laboratorios Pasteur, Laboratorios Bussie, Labinco, Pharmadorf, and IDISA Group.

Product and service23 records
1Sanfer Conecta
CategoryDigital platform for healthcare professionals
Description

Free mobile application for healthcare professionals offering access to Sanfer's prescription and OTC product catalog, a virtual library of more than 300,000 medical books and articles, on-demand webinars, and interactive 3D anatomical models.

2Sanfer Salud Animal
CategoryAnimal health pharmaceuticals and vaccines
Description

Animal health division providing live vaccines, recombinant vaccines, emulsified vaccines, bacterins, specific immunoglobulins, sterile diluents, antibiotics, antiparasitics, hormonal products, mastitis diagnostic tests, biosecurity products, antimycotoxin agents, and nutritional additives for veterinarians and animal health providers.

3Sanfer ALPES and Sanfer IMSA (Avian Genetics)
CategoryAvian genetics and poultry production
Description

Poultry genetics businesses (ALPES and IMSA) offering poultry genetic lines for the human pharmaceutical, animal health, and agricultural markets.

4AC-Fast
CategoryOTC analgesic
Description

OTC analgesic tablets containing Paracetamol 500mg, available in 10-tablet packs, for headache, muscle pain, toothache, ear pain, and fever reduction.

5Algitrin
CategoryOTC analgesic
Description

OTC analgesic for temporary relief of mild to moderate pain (headache, muscle, dental, back, menstrual, and joint pain) and fever reduction, containing Paracetamol/Ibuprofen, available in 12- and 24-tablet packs.

6Andantol
CategoryOTC antihistamine
Description

OTC antihistamine (4mg tablets, jelly, gel, and syrup formulations) for effective relief of allergy symptoms such as sneezing, runny nose, watery eyes, itching in nose and throat, and urticaria.

7Biometrix
CategoryNutraceutical supplement
Description

Nutraceutical food supplement line based on vitamins, minerals, and ginseng, available in Performance, AOX (with antioxidants), and Q-10 (with Coenzyme Q-10 and royal jelly) formulations in 30- and 100-capsule presentations.

8Tabalón
CategoryOTC anti-inflammatory analgesic
Description

OTC anti-inflammatory analgesic containing Ibuprofen 400mg tablets for treatment of fever, inflammation, and relief of various pains including headache (including migraine), toothache, muscle pain, and premenstrual pain.

9Desenex
CategoryOTC antifungal
Description

OTC antifungal cream containing undecylenic acid and zinc undecylenate, available in 28g and 48g tubes, for treatment of dry lesions of cutaneous mycosis (tineas) affecting the skin and as auxiliary treatment of Athlete's Foot.

10Treda
CategoryOTC gastrointestinal medication
Description

OTC antiseptic intestinal medication for acute diarrhea with or without infection, containing Neomycin, Kaolin, and Pectin, available in suspension (almond-cherry flavor, 75ml) and tablets (10 and 20 tablets).

11Ting
CategoryOTC antifungal
Description

OTC antifungal powder and cream for treatment of Athlete's Foot and other superficial mycoses (tineas), containing undecylenic acid, zinc undecylenate, and triclosan, available in 45g/85g/160g powder and 28g/72g cream formats.

12Syncol
CategoryOTC women's health medication
Description

OTC line of products for premenstrual syndrome (PMS) and dysmenorrhea, including Syncol (Paracetamol/Pyrilamine/Pamabrom), Syncol Max, Syncol Nocturno, and Syncol Dual (Naproxen Sodium/Paracetamol).

13Optazol-KO
CategoryOTC gastrointestinal medication
Description

OTC intestinal antiseptic for acute diarrhea with or without mild infection, containing Neomycin, Kaolin, and Pectin, available in suspension (75ml) and 20-tablet (129/280/30 mg) presentations.

14Mebeciclol
CategoryPrescription antiparasitic
Description

Prescription treatment for intestinal parasitosis, containing Mebendazole and Tinidazole in 18-tablet packs of 300mg/60mg.

15Loxcell NF
CategoryPrescription antiparasitic
Description

Prescription anti-parasitic medication for treatment of parasitosis caused by protozoa and helminths including Taenia (tapeworm), pinworm, Ascaris, and Giardia, 1 tablet of 400/300mg.

16Meta-R
CategoryNutraceutical supplement
Description

Metabiotics food supplement containing Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus fermentum, and polyphenol complex, presented as 90 capsules with 30 day capsules and 60 night capsules.

17Microdacyn
CategoryOTC wound care antiseptic
Description

OTC wound cleansing and healing antiseptic solution for adjuvant treatment of all types of wounds (superficial, acute, chronic, and/or deep), available in 120ml/240ml spray solution, 100g Hydrogel, and a bucopharyngeal formulation.

18Mucosolvan
CategoryOTC expectorant
Description

OTC expectorant containing Ambroxol, available in 120ml solution (300mg/100ml or 600mg/100ml), auxiliary for relief of productive cough by dissolving and helping expel phlegm.

19Bisolvon
CategoryOTC expectorant
Description

OTC expectorant containing Bromhexine for expectoration of phlegm, available in adult solution (120ml) and children's solution (120ml).

20Sinudox
CategoryOTC nasal antiseptic
Description

OTC nasal antiseptic solution auxiliary in prevention and treatment of rhinopharyngeal infections (common cold, rhinopharyngitis, rhinitis, sinusitis), nasal hygiene, and treatment of nasal surgical wounds, presented as 60ml spray.

21Eternal
CategoryNutraceutical supplement
Description

OTC Vitamin E antioxidant supplement containing Tocofersolan for treatment of vitamin E deficiencies, available in 30- and 99-capsule packs.

22Lonol
CategoryOTC topical anti-inflammatory
Description

OTC topical line for relief of muscle and joint pain, including Lonol cream (Benzydamine 60g) and Lonol Sport gel (Benzydamine, Menthol, Methyl Salicylate, 30g).

23Efpeglenatide (GLP-1 Therapy)
CategoryPrescription metabolic therapy
Description

Hanmi Pharmaceutical's GLP-1 therapy for obesity, distributed in Mexico exclusively by Laboratorios Sanfer under an exclusive distribution agreement announced in 2026. Sanfer leads regulatory approvals, marketing, and sales while Hanmi supplies the finished formulation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-06
Description

Hanmi Pharmaceutical signed an exclusive distribution agreement with Laboratorios Sanfer to introduce efpeglenatide, a GLP-1 therapy for obesity, in Mexico. Sanfer leads regulatory approvals, marketing, and sales efforts in Mexico while Hanmi supplies the finished formulations. The partnership aims to address rising demand for metabolic treatments in Mexico, which has 36.86% obesity prevalence and 16.4% diabetes prevalence. Both companies plan to gradually expand collaboration on metabolic disease treatments and explore additional product launches over the medium to long term.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-28
Description

Exclusive distribution agreement for Hanmi's GLP-1 obesity drug efpeglenatide and Dapalon-lineup diabetes treatments in Mexico. Hanmi supplies finished formulations while Sanfer handles regulatory approvals, marketing, and sales. Mexico's high obesity (36.86%) and diabetes (16.4%) prevalence makes it a strategically valuable market for Hanmi's independently developed GLP-1 treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mexican pharmaceutical company with a similar OTC and consumer healthcare portfolio, plus a strong Latin American distribution footprint. Highly comparable in geographic focus, customer segments (pharmacies and mass retail), and product positioning.

2Laboratorios Liomont
TypeDirect peer
Description

Mexican pharmaceutical manufacturer with a comparable product mix spanning prescription, OTC, and animal health products, and a similar focus on the Mexican and Central American markets. Closely aligned in scale, business model, and therapeutic breadth.

3Grupo PISA
TypeDirect peer
Description

One of the largest sterile injectable manufacturers in Latin America, headquartered in Mexico. Directly comparable to Sanfer following the Vitalis acquisition given its leadership in injectables manufacturing and hospital channel distribution.

4Eurofarma Laboratórios
TypeRegional player
Description

Brazilian multinational pharmaceutical company with broad prescription, OTC, and generics portfolio and Latin American regional presence. Comparable in business model, therapeutic breadth, and Latin American growth strategy, though primarily Brazil-anchored.

TypeRegional player
Description

Brazil's largest pharmaceutical company by volume, with a comprehensive generics, prescription, and OTC portfolio. Comparable as a Latin American pharma market leader with broad therapeutic coverage and mass-market distribution.

TypeRegional player
Description

Argentine pharmaceutical multinational with operations across Latin America, manufacturing prescription and OTC products. Similar in business model and regional expansion strategy, with comparable focus on ethical pharmaceuticals across the Southern Cone.

TypeRegional player
Description

Argentine pharmaceutical group with branded prescription, OTC, and consumer health products marketed across Latin America. Comparable in pharmaceutical manufacturing, therapeutic breadth, and multi-country Latin American commercial presence.

TypeBroad incumbent
Description

Global pharmaceutical major with a meaningful Latin American branded prescription and consumer health business. Comparable in therapeutic categories and distribution model, but operates at much greater scale with a global R&D engine.

TypeBroad incumbent
Description

Global healthcare and pharmaceutical major with strong OTC and consumer health presence in Latin America. Comparable in OTC product categories, pharmacy distribution, and consumer health marketing, though with a far broader portfolio.

TypeBroad incumbent
Description

Global leader in generics and specialty pharmaceuticals with established operations in Latin America. Comparable in prescription generics, manufacturing scale, and supply-chain capability, though far larger and more globally diversified.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries18 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanfer

Pharmaceuticalssanfer.com.mx

Sanfer is a privately held Mexican multinational pharmaceutical company founded in 1941 that manufactures and distributes prescription, OTC, animal health, and biologic products through 20 manufacturing sites across 25+ countries, serving consumers, healthcare professionals, and veterinarians in Latin America.

What Sanfer does

Laboratorios Sanfer, S.A. de C.V. is a privately held Mexican multinational pharmaceutical company founded in 1941, headquartered in Mexico City, with operations in more than 25 countries across Latin America, the Caribbean, North America, Europe, Africa, the Middle East, and Asia. The company manufactures, markets, and distributes prescription medications, over-the-counter (OTC) consumer health products, animal health products (vaccines, antibiotics, antiparasitics, diagnostics), and poultry genetics through 20 manufacturing sites and a workforce of more than 12,000 employees. Sanfer's therapeutic footprint spans sterile injectables (ampoules, vials, lyophilized, prefilled syringes), oral solids and suspensions, semisolids, soft gelatin capsules, oncological steriles, antibiotics, and biologics, with capabilities reinforced by acquisitions including Probiomed (biotech, 2021) and Vitalis (Colombian sterile injectables leader, 2024).

Sanfer operates through a portfolio of legacy and acquired brands — including Mavi Farmacéutica, More Pharma, Pharmadorf (Argentina), Laboratorios Bussie and Labinco (Colombia), Laboratorios Pasteur (Chile), and Laboratorios Portugal (Peru) — alongside sub-brands such as Sanfer Salud Animal, Sanfer ALPES/IMSA (poultry genetics), and Sanfer Conecta (a digital platform providing healthcare professionals with access to more than 300,000 medical books, articles, webinars, and 3D anatomical models). The company sells through a multi-channel distribution network: retail pharmacy chains, mass retailers, e-commerce platforms (Amazon, Cornershop, Rappi, Farmalisto), and the Sanfer Conecta app for healthcare professionals.

Sanfer's commercial model is a sales-led, multi-channel distribution operation across prescription, OTC, animal health, and biologics, with revenue derived from unit sales of branded pharmaceutical products to consumers via pharmacies and retailers, to veterinarians and animal health providers, and to healthcare institutions across Latin America. Quality and regulatory certifications from COFEPRIS, INVIMA, DIGEMID, EMA, ISO, and FAMI-QS underpin the international expansion. The company has pursued an aggressive inorganic growth strategy, backed by institutional capital from La Caisse and General Atlantic (a $500M round in 2019), with recent strategic moves including the Vitalis acquisition (2024) and an exclusive distribution partnership with Hanmi Pharmaceutical for GLP-1 and diabetes therapies in Mexico (2026).

Sanfer firmographics

Firmographics
Name
Sanfer
Legal name
Laboratorios Sanfer, S.A. de C.V.
Website
https://sanfer.com.mx
Company type
Private
Founded year
1941
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Sanfer is a privately held Mexican multinational pharmaceutical company founded in 1941 that manufactures and distributes prescription, OTC, animal health, and biologic products through 20 manufacturing sites across 25+ countries, serving consumers, healthcare professionals, and veterinarians in Latin America.
Ownership category
akta.pro rank

Sanfer industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Animal Food Manufacturing (3111)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
SECONDARYHLAMAKAI
Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO)

Keywords

  • Prescription pharmaceuticals
  • Over-the-counter medications
  • Animal health products
  • Sterile injectables manufacturing
  • Pharmaceutical distribution

Where Sanfer is headquartered

Location

Headquarters

HQ city
Mexico City
HQ country
Mexico
HQ region
Latin America

Offices9 records

Markets served

Sanfer business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Medications: Prescription pharmaceutical products sold through pharmacies and healthcare providers in Mexico and Latin America
  2. Over-the-Counter (OTC) Products: OTC pharmaceutical and consumer health products sold directly to consumers through pharmacies and retail chains
  3. Animal Health Products: Veterinary pharmaceuticals, vaccines, and health products for animals sold to veterinarians and animal health providers
  4. Poultry Genetics: Poultry genetics products through Sanfer ALPES and IMSA for the pharmaceutical and agricultural markets

Go-to-market motion1 record

Distribution channels6 records

Marketing channels8 records

Sanfer product offering

Product offering

Core offering

Laboratorios Sanfer manufactures, markets, and sells branded prescription and over-the-counter pharmaceutical products across multiple therapeutic areas through 20 manufacturing sites in Mexico and Latin America. The company also produces animal health pharmaceuticals, vaccines, and diagnostics through its Sanfer Salud Animal division, and operates integrated poultry genetics businesses (Sanfer ALPES and Sanfer IMSA). It supplements its product portfolio with the Sanfer Conecta digital platform that gives healthcare professionals access to product information, a medical library, and clinical resources.

Product overview

Laboratorios Sanfer is a leading Mexican pharmaceutical company with operations in 25+ countries across Latin America, operating as a diversified pharmaceutical group. The company offers a comprehensive portfolio of prescription medications, OTC (over-the-counter) products, nutraceuticals/supplements, and animal health products through multiple divisions and acquired brands. The core product ecosystem includes Sanfer Conecta, a digital platform for healthcare professionals providing access to product catalogs, medical libraries, webinars, and 3D anatomical models. The OTC portfolio includes analgesic/antipyretic products (AC-Fast, Algitrin, Tabalón, Lonol), antihistamines (Andantol), gastrointestinal products (Treda, Optazol-KO), antifungal products (Desenex, Ting), and wound care products (Microdacyn). The nutraceutical line includes Biometrix variants (Performance, AOX, Q-10), Meta-R metabiotics, and Eternal Vitamin E supplements. Animal health offerings are provided through Sanfer Salud Animal with vaccines, antibiotics, and diagnostic products. Sanfer has expanded through strategic acquisitions including Vitalis (sterile injectables), Probiomed (biotech), Mavi Farmacéutica, More Pharma, Laboratorios Portugal, Laboratorios Pasteur, Laboratorios Bussie, Labinco, Pharmadorf, and IDISA Group.

Differentiator

Problem solved

Functional benefit

Brands

  • Sanfer ALPES: Poultry genetics company
  • Sanfer IMSA
  • Sanfer Salud Animal
  • Sanfer Conecta
  • Fundación Sanfer

Products and services

  • Sanfer Conecta Free mobile application for healthcare professionals offering access to Sanfer's prescription and OTC product catalog, a virtual library of more than 300,000 medical books and articles, on-demand webinars, and interactive 3D anatomical models.
  • Sanfer Salud Animal Animal health division providing live vaccines, recombinant vaccines, emulsified vaccines, bacterins, specific immunoglobulins, sterile diluents, antibiotics, antiparasitics, hormonal products, mastitis diagnostic tests, biosecurity products, antimycotoxin agents, and nutritional additives for veterinarians and animal health providers.
  • Sanfer ALPES and Sanfer IMSA (Avian Genetics) Poultry genetics businesses (ALPES and IMSA) offering poultry genetic lines for the human pharmaceutical, animal health, and agricultural markets.
  • AC-Fast OTC analgesic tablets containing Paracetamol 500mg, available in 10-tablet packs, for headache, muscle pain, toothache, ear pain, and fever reduction.
  • Algitrin OTC analgesic for temporary relief of mild to moderate pain (headache, muscle, dental, back, menstrual, and joint pain) and fever reduction, containing Paracetamol/Ibuprofen, available in 12- and 24-tablet packs.
  • Andantol OTC antihistamine (4mg tablets, jelly, gel, and syrup formulations) for effective relief of allergy symptoms such as sneezing, runny nose, watery eyes, itching in nose and throat, and urticaria.
  • Biometrix Nutraceutical food supplement line based on vitamins, minerals, and ginseng, available in Performance, AOX (with antioxidants), and Q-10 (with Coenzyme Q-10 and royal jelly) formulations in 30- and 100-capsule presentations.
  • Tabalón OTC anti-inflammatory analgesic containing Ibuprofen 400mg tablets for treatment of fever, inflammation, and relief of various pains including headache (including migraine), toothache, muscle pain, and premenstrual pain.
  • Desenex OTC antifungal cream containing undecylenic acid and zinc undecylenate, available in 28g and 48g tubes, for treatment of dry lesions of cutaneous mycosis (tineas) affecting the skin and as auxiliary treatment of Athlete's Foot.
  • Treda OTC antiseptic intestinal medication for acute diarrhea with or without infection, containing Neomycin, Kaolin, and Pectin, available in suspension (almond-cherry flavor, 75ml) and tablets (10 and 20 tablets).
  • Ting OTC antifungal powder and cream for treatment of Athlete's Foot and other superficial mycoses (tineas), containing undecylenic acid, zinc undecylenate, and triclosan, available in 45g/85g/160g powder and 28g/72g cream formats.
  • Syncol OTC line of products for premenstrual syndrome (PMS) and dysmenorrhea, including Syncol (Paracetamol/Pyrilamine/Pamabrom), Syncol Max, Syncol Nocturno, and Syncol Dual (Naproxen Sodium/Paracetamol).
  • Optazol-KO OTC intestinal antiseptic for acute diarrhea with or without mild infection, containing Neomycin, Kaolin, and Pectin, available in suspension (75ml) and 20-tablet (129/280/30 mg) presentations.
  • Mebeciclol Prescription treatment for intestinal parasitosis, containing Mebendazole and Tinidazole in 18-tablet packs of 300mg/60mg.
  • Loxcell NF Prescription anti-parasitic medication for treatment of parasitosis caused by protozoa and helminths including Taenia (tapeworm), pinworm, Ascaris, and Giardia, 1 tablet of 400/300mg.
  • Meta-R Metabiotics food supplement containing Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus fermentum, and polyphenol complex, presented as 90 capsules with 30 day capsules and 60 night capsules.
  • Microdacyn OTC wound cleansing and healing antiseptic solution for adjuvant treatment of all types of wounds (superficial, acute, chronic, and/or deep), available in 120ml/240ml spray solution, 100g Hydrogel, and a bucopharyngeal formulation.
  • Mucosolvan OTC expectorant containing Ambroxol, available in 120ml solution (300mg/100ml or 600mg/100ml), auxiliary for relief of productive cough by dissolving and helping expel phlegm.
  • Bisolvon OTC expectorant containing Bromhexine for expectoration of phlegm, available in adult solution (120ml) and children's solution (120ml).
  • Sinudox OTC nasal antiseptic solution auxiliary in prevention and treatment of rhinopharyngeal infections (common cold, rhinopharyngitis, rhinitis, sinusitis), nasal hygiene, and treatment of nasal surgical wounds, presented as 60ml spray.
  • Eternal OTC Vitamin E antioxidant supplement containing Tocofersolan for treatment of vitamin E deficiencies, available in 30- and 99-capsule packs.
  • Lonol OTC topical line for relief of muscle and joint pain, including Lonol cream (Benzydamine 60g) and Lonol Sport gel (Benzydamine, Menthol, Methyl Salicylate, 30g).
  • Efpeglenatide (GLP-1 Therapy) Hanmi Pharmaceutical's GLP-1 therapy for obesity, distributed in Mexico exclusively by Laboratorios Sanfer under an exclusive distribution agreement announced in 2026. Sanfer leads regulatory approvals, marketing, and sales while Hanmi supplies the finished formulation.

Companies that use Sanfer

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Sanfer technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Sanfer partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Hanmi PharmaceuticalcoreStrategic or Co-development Partner · 6 February 2026Hanmi Pharmaceutical signed an exclusive distribution agreement with Laboratorios Sanfer to introduce efpeglenatide, a GLP-1 therapy for obesity, in Mexico. Sanfer leads regulatory approvals, marketing, and sales efforts in Mexico while Hanmi supplies the finished formulations. The partnership aims to address rising demand for metabolic treatments in Mexico, which has 36.86% obesity prevalence and 16.4% diabetes prevalence. Both companies plan to gradually expand collaboration on metabolic disease treatments and explore additional product launches over the medium to long term.
  • Hanmi PharmaceuticalcoreStrategic or Co-development Partner · 28 January 2026Exclusive distribution agreement for Hanmi's GLP-1 obesity drug efpeglenatide and Dapalon-lineup diabetes treatments in Mexico. Hanmi supplies finished formulations while Sanfer handles regulatory approvals, marketing, and sales. Mexico's high obesity (36.86%) and diabetes (16.4%) prevalence makes it a strategically valuable market for Hanmi's independently developed GLP-1 treatment.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Sanfer competitors and assessment

Company assessment

Direct peers

  • Genomma Lab Internacional: Mexican pharmaceutical company with a similar OTC and consumer healthcare portfolio, plus a strong Latin American distribution footprint. Highly comparable in geographic focus, customer segments (pharmacies and mass retail), and product positioning.
  • Laboratorios Liomont: Mexican pharmaceutical manufacturer with a comparable product mix spanning prescription, OTC, and animal health products, and a similar focus on the Mexican and Central American markets. Closely aligned in scale, business model, and therapeutic breadth.
  • Grupo PISA: One of the largest sterile injectable manufacturers in Latin America, headquartered in Mexico. Directly comparable to Sanfer following the Vitalis acquisition given its leadership in injectables manufacturing and hospital channel distribution.

Regional players

  • Eurofarma Laboratórios: Brazilian multinational pharmaceutical company with broad prescription, OTC, and generics portfolio and Latin American regional presence. Comparable in business model, therapeutic breadth, and Latin American growth strategy, though primarily Brazil-anchored.
  • EMS Pharma: Brazil's largest pharmaceutical company by volume, with a comprehensive generics, prescription, and OTC portfolio. Comparable as a Latin American pharma market leader with broad therapeutic coverage and mass-market distribution.
  • Laboratorios Bagó: Argentine pharmaceutical multinational with operations across Latin America, manufacturing prescription and OTC products. Similar in business model and regional expansion strategy, with comparable focus on ethical pharmaceuticals across the Southern Cone.
  • Roemmers: Argentine pharmaceutical group with branded prescription, OTC, and consumer health products marketed across Latin America. Comparable in pharmaceutical manufacturing, therapeutic breadth, and multi-country Latin American commercial presence.

Broad incumbents

  • Sanofi: Global pharmaceutical major with a meaningful Latin American branded prescription and consumer health business. Comparable in therapeutic categories and distribution model, but operates at much greater scale with a global R&D engine.
  • Bayer Pharmaceuticals: Global healthcare and pharmaceutical major with strong OTC and consumer health presence in Latin America. Comparable in OTC product categories, pharmacy distribution, and consumer health marketing, though with a far broader portfolio.
  • Teva Pharmaceutical: Global leader in generics and specialty pharmaceuticals with established operations in Latin America. Comparable in prescription generics, manufacturing scale, and supply-chain capability, though far larger and more globally diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

Sanfer social profiles

Digital presence

Sanfer compliance and trust

Trust signal

Compliance5 records

Sanfer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanfer leadership team

Management profile

Number of profiles

Profiles2 records

Sanfer subsidiaries and ownership

Company hierarchy

Subsidiaries18 records

Sanfer funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanfer M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanfer

What does Sanfer do?

Laboratorios Sanfer manufactures, markets, and sells branded prescription and over-the-counter pharmaceutical products across multiple therapeutic areas through 20 manufacturing sites in Mexico and Latin America. The company also produces animal health pharmaceuticals, vaccines, and diagnostics through its Sanfer Salud Animal division, and operates integrated poultry genetics businesses (Sanfer ALPES and Sanfer IMSA). It supplements its product portfolio with the Sanfer Conecta digital platform that gives healthcare professionals access to product information, a medical library, and clinical resources.

Is Sanfer a public or private company?

Sanfer is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sanfer founded?

Sanfer was founded in 1941. It employs 1,001 to 5,000 people.

Where is Sanfer based?

Sanfer is headquartered in Mexico City, Mexico, in the Latin America region.

How does Sanfer make money?

Four revenue lines are on record. Prescription Medications are the primary driver. The others are over-the-Counter (OTC) Products, animal Health Products and poultry Genetics.

Who are Sanfer's main competitors?

Direct peers on record are Genomma Lab Internacional, Laboratorios Liomont and Grupo PISA. Regional players are Eurofarma Laboratórios, EMS Pharma, Laboratorios Bagó and Roemmers. Broad incumbents are Sanofi, Bayer Pharmaceuticals and Teva Pharmaceutical.

Does Sanfer have an API?

No public API is recorded for Sanfer.

What industry is Sanfer in?

Sanfer's product category is Pharmaceuticals. Its primary akta.pro industry code is AFAEANAK, Veterinary Pharmacy, Vaccine & Biologics Services, with a secondary code of HLAMAKAI, Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mexico Business NewsMexico's Obesity Response Becomes a Business Inflection PointMexico's Ministry of Health raised the excise tax on sugar-sweetened beverages from MX$1 to MX$3.1 per liter as part of the 2026 economic package, prompting PepsiCo and GEPP to undertake their most significant beverage reformulation in over a decade, while the National Alliance of Small Merchants reported price shocks pushing consumers toward cheaper brands. Eli Lilly has named Mexico a priority market targeting US$2 billion in revenue by 2030, Novo Nordisk has launched semaglutide 2.4mg for weight management, and Hanmi Pharmaceutical entered through an exclusive distribution agreement with Laboratorios Sanfer for GLP-1 therapy efpeglenatide. With 37% of Mexican adults living with obesity and multiple regulatory tracks including food labeling and school procurement guidelines still advancing, food, beverage, retail, and healthcare companies face sustained compliance costs alongside expanding demand for clinical treatment services through 2030.Mexico Business NewsHanmi, Sanfer Partner to Bring GLP-1 Therapy to MexicoHanmi Pharmaceutical signed an exclusive distribution agreement with Mexico-based Laboratorios Sanfer to introduce efpeglenatide, a GLP-1 therapy for obesity, in Mexico. The partnership aims to address rising demand for metabolic treatments in a high-burden market and involves Sanfer leading regulatory, marketing, and sales efforts while Hanmi supplies the product.KBRHanmi Pharm signs exclusive Mexico deal for GLP-1 obesity drug efpeglenatideHanmi Pharmaceutical signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for its GLP-1 obesity drug efpeglenatide and Dapalon-lineup diabetes treatments, with Hanmi supplying finished formulations and Sanfer handling regulatory approvals, marketing, and sales in Mexico. Mexico has high obesity prevalence at 36.86 percent and diabetes prevalence at 16.4 percent, making it a strategically valuable market for Hanmi's independently developed GLP-1 treatment. Both companies plan to gradually expand collaboration on metabolic disease treatments and explore additional product launches over the medium to long term.PR NewswireHanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and MoreHanmi Pharmaceutical has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide (its GLP-1 obesity therapy) and the Dapalon Family diabetes treatments, with Hanmi supplying the products and Sanfer handling regulatory approval, marketing, distribution, and sales within Mexico. The partnership targets Mexico's high obesity prevalence of 36.86% and diabetes prevalence of 16.4%, with collaboration expected to expand across Latin America over the mid- to long term. Hanmi is targeting obesity approval for efpeglenatide in the second half of 2026 and an additional diabetes indication in 2028.PR NewswireACON Investments Signs Definitive Agreement to Sell Vitalis to Laboratorios SanferACON Investments has signed a definitive agreement to sell Vitalis, a manufacturer of injectable pharmaceuticals in Colombia and Mexico, to Mexican multinational Laboratorios Sanfer. The transaction is subject to approval by antitrust authorities in Colombia and Mexico, with financial terms undisclosed. This sale marks the first exit from ACON's fifth regional investment fund.PR NewswireSanfer recibe USD $500 millones de CDPQ para financiar el crecimiento estratégico en América LatinaSanfer, a leading Mexican pharmaceutical company, announced it has secured a USD $500 million minority investment from Caisse de dépôt et placement du Québec (CDPQ) to fund strategic expansion in Mexico and Latin America. This transaction, one of the largest private equity minority operations in Mexican history, will allow Sanfer to accelerate growth through organic sources and future acquisitions while General Atlantic retains its existing stake.PR NewswireSanfer receives USD $500 million from CDPQ to fund strategic growth across Latin AmericaSanfer, a leading Mexican pharmaceutical company, secured a USD $500 million minority investment from Caisse de dépôt et placement du Québec (CDPQ) to fund strategic expansion across Mexico and Latin America. This transaction, described as one of the largest minority private equity deals in Mexico, will enable Sanfer to accelerate both organic growth and further acquisitions alongside existing partner General Atlantic.